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A homeopathic combination preparation (HCP) for canine osteoarthritic pain was evaluated
in a randomized, double-controlled and double-blinded clinical trial. Forty-four dogs
with osteoarthritis (OA) that were randomly allocated into one of three groups completed
the study. All dogs were fed test products or placebo for 8 weeks. The dogs were evaluated at
the clinic four times, with 4-week intervals. Six different variables were assessed: veterinary-
assessed mobility, two force plate variables, an owner-evaluated chronic pain index and pain
and locomotion visual analogue scales (VASs). Intake of extra non-steroidal anti-inflammatory
drugs was also evaluated. A Chi-squared test and a Mann–Whitney test were used to determine
significant improvement between groups. When changed into dichotomous responses of
‘improved’ or ‘not improved’ three out of the six variables showed a significant difference
(P=0.016, P=0.008, P=0.039) in improved dogs per group, between the HCP group
and the placebo group. The odds ratios were over one for the same variables. As extent of
improvement in the variables from start to end of treatment, the HCP product was significantly
more improved in four (P=0.015, P=0.028, P=0.049, P=0.020) of the six variables,
compared with the placebo. Our results indicated that the HCP Zeel was beneficial in
alleviating chronic orthopedic pain in dogs although it was not as effective as carprofen.
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Introduction
We analyzed the use of a low-dilution complex formula-
tion, the homeopathic combination preparation (HCP)
Zeel (1) for the treatment of osteoarthritis (OA) in dogs.
OA is today the most common joint disease affecting
dogs (2), with canine hip dysplasia (CHD) and elbow
dysplasia (ED) being two common variants. In spite of
the prevalence and seriousness of canine OA, to date, no
research has been published on the effects of homeopathy
on OA in dogs (3). In contrast, there is a growing body
of research in human medicine on the utilization of
homeopathy in general and for OA in particular [for an
excellent lecture series on homeopathy and inflammatory
diseases, see (4–9) and their references]. Comprehensive
meta-analyses of the use of homeopathy on humans have
indicated that homeopathy indeed has a positive input on
a range of diseases (10,11), whereas others have shown
the opposite (12). Two double-blind studies have been
conducted specifically on HCP Zeel in human patients
suffering from OA. A therapeutic equivalence was found
between Zeel and the non-steroidal anti-inflammatory
drug (NSAID) Diclofenac (13). In another comparative
trial on human OA, Zeel comp. was found to be as
good as hyaluronic acid (14). Neither of these trials
included placebo groups. It has been recommended for
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properly cited.human use (15) and also used on rabbits (16) and
horses (17).
Our aim was to evaluate the Zeel HCP as a therapy
for canine OA, using a randomized, double-controlled
and double-blinded clinical trial (18–22). Based on
previous research, we hypothesized a positive effect
of HCP. In addition to a placebo group as a negative
control, we included an established canine analgesic as a
positive control so as to further explore the impact of the
treatment. It should be stressed that this is not a classical
homeopathic treatment either in the sense of using one
drug at a time or in that it is extremely diluted; the
product used here was a complex combination and only
diluted until molar concentrations of 10
5–10
12mol/l.
Subjects and Methods
Dogs
Inclusion criteria were that dogs have clinical signs and
a radiographic diagnosis of OA in either a hip joint or
an elbow joint (23). The owner had to have described
at least two of the following signs as being chronic or
frequent: difficulty in lying down and/or in getting up
from a lying position, difficulty in jumping or refusing to
jump, difficulty in walking up or down stairs, or definite
lameness. Dogs were excluded from the study if they
had had prior surgery on the evaluated joint, inadequate
clinical symptoms, systemic or infectious disease, neuro-
logical deficits, lameness from articular infection, or
recent trauma. In this study, 51 dogs were included and
44 concluded the study. Baseline data in Table 1.
Test Products and Treatment Regime
The groups of dogs were medicated as follows: the active
treatment group was given the HCP (Zeel ad us. vet.
5ml, Biologishce Heilmittel Heel GmbH, Baden-Baden,
Germany, see Table 2) at a dose of ½–1 ampoule/day
[<25kg or >25kg body weight (BW)] given once daily.
The positive control was given a canine NSAID,
carprofen (Rimadyl 50mg, Pfizer, Helsinki, Finland),
at a dose of 2mg/kg twice daily. The products differed
from each other in form; the carprofen and its placebo
(lactose) came as a white pill, the HCP and its placebo
(an isotonic sodium chloride solution) as an ampoule of
clear liquid. Further, all dogs received a slightly green
(lactose) capsule, that acted placebo for a parallel study
(24). All dogs in the treatment groups were administered
three products; one real and two placebos. In the
negative control (placebo) group, all products adminis-
tered were placebos. The products were coded and
assembled by a research assistant who was not involved
in the rest of the study. For ethical reasons, all owners
were given a supplementary package of the same NSAID
carprofen (Rimadyl) in normal packaging at the start of
the trial. This could be used as additional pain relief
(dose of 1 tablet for a dog of 20–30kg, 2 tablets for a dog
of 31–40kg and 3 tablets for a dog of 41–60kg) if the
dog was in considerable pain, but this had to be recorded
in the questionnaires.
Study Protocol
Prior to the study, candidates were screened through
telephone interviews. Owners were asked not to give the
dogs NSAIDs or corticosteroids for at least 30 days and
no Na-pentosan polysulfate (Carthrophen, Biopharm
Australia Pty. Ltd., Australia) for at least 90 days prior
to the initiation of the study.
The first questionnaire was answered at home
4 weeks before the trial started (W4). The following
four questionnaires where answered at the follow ups, at
4-week intervals (W0, W4, W8 and W12). An assistant
made the first appointments for the dogs, which were
then allocated, in order of arrival, into the groups using
a computer-generated random list. Only the location of
Table 1. Baseline data for all three groups
Possible confounding
factors at baseline
Carprofen HCP Placebo
n 15 14 15
hip OA/elbow OA (n) 12/3 12/2 12/3
Sex: male/female 7/8 8/7 10/5
Median age (years), 5 7,5 6
Min–Max 1–9 1–11 1–11
Median duration of
signs (years)
>2 1–2 1–2
Median weight (kg), 38 27,5 34
Min–Max 31–56 22–54 18–54
MeanSD of continuous variables at start of trial
Veterinary-assessed
mobility index
a
5.004.61 6.796.46 5.204.26
Force plate–PVF
b 75.9223.48 70.9622.58 78.4622.23
Force plate–impulse
b 10.924.02 8.643.06 9.723.43
Chronic pain index
a 16.476.21 15.866.20 14.874.79
Pain VAS (cm)
a 3.552.17 4.242.16 3.701.77
Locomotion VAS (cm)
a 4.572.03 4.872.26 4.612.12
Median, Min–Max of variable at 4 weeks prior to trial (W4)
NSAID doses
per month
none, none
to 3–5/week
none, none to
daily/almost
daily
none, none
to about
1/week
Distribution of possible confounding factors between groups at time
W0 (for extra NSAIDs at W4). HCP, homeopathic combination
preparation; NSAID, non-steroidal anti-inflammatory drugs; OA,
osteoarthritis; PVF, peak vertical force; VAS, visual analogue scale.
aA higher value means more pain.
bA lower value means more pain.
466 Zeel for canine osteoarthritisdiagnosed OA (hip or elbow) was stratified in the
randomization. At W0 initial clinical, orthopedic and
neurological examinations were performed and diagnostic
criteria included decreased range of motion and pain on
stretching the hip or flexing the elbow. The hip and
elbow, as well as all other limb joints, were evaluated for
pain, swelling and/or crepitus. Radiographs of the dogs’
hips and/or elbows, and other joints if needed, were
taken only at time W0. The W0 evaluation and W0
questionnaire was set as baseline, except for extra
carprofen where W4 was used as baseline. The dogs
were then given the products orally from W0 to W8.A t
W12, the dogs had been washed off from all medica-
tion for 4 weeks and were evaluated to determine possible
long-term effects of the different treatments. All evalua-
tors (veterinarians and owners) and trial personnel
were blinded. Owners of the dogs were required to sign
informed consent forms. The study protocol was
approved by the Ethics Committee of the University of
Helsinki.
Veterinary Evaluation
Two veterinarians subjectively assessed locomotion,
jumping and walking stairs at W0, W4, W8 and W12,
using 5-point scales where 0=normal and 4=dog is
totally lame/does not jump at all/does not walk stairs
at all (24). The evaluations of the two veterinarians
correlated well (R=0.853, P<0.01). The three scores
assigned by the two veterinarians were summed to form
a veterinary-assessed mobility index [23(0 to 4)].
Owner Evaluation
The questionnaire consisted of three parts. First, the
owners responded to 18 questions about attitude,
behavior and locomotion using a descriptive scale from
0 to 4. Of these, 11 questions were combined to form a
validated owner-assessed chronic pain index (25). The
second part contained two 10-cm visual analogue scales
(VASs): one for pain and the other for locomotion. The
end of the lines to the left (0cm) represented no pain or
difficulties in locomotion and to the right (10cm), the
worst possible pain or the most severe difficulties in
locomotion. The third part consisted of five questions
about possible adverse reactions to treatment, including
change in appetite, vomiting, diarrhoea, atopic skin
reactions and the need for extra carprofen. The question
about extra analgesics used the following scale: during
the last 4 weeks, additional carprofen was given; 1=not
at all, 2=1–2 times, 3=about once a week, 4=about
3–5 times a week and 5=daily/almost daily.
Objective Evaluation of Gait
Gait was analyzed by force plate gait analysis (Kistler
force plate Type 9286, Kistler Instrumente AG
Winterhur, CH-8408, Switzerland), which objectively
assesses weight bearing of limbs. The signal from the
plate was processed and stored using a computer-based
software program, and velocities and acceleration were
determined by three photoelectric cells placed 1m apart
and a start-interrupt timer system (Aquire 6.0, Sharon
Software Inc., DeWitt, USA). The dogs were trotted
from left to right by their owners. The speed had to be in
the same range (0.5m/s) for the dog each time the test
was performed (at W0, W4, W8 and W12). The accelera-
tion was <0.5m/s/s and there had to be contact with the
plate first by the forelimb and shortly after with the hind
limb of the same side for the evaluation to be valid. The
test was repeated until sufficient valid results were
obtained for both left and right limbs. Three valid
measurements for each side and for each visit were then
chosen by a blinded assistant, who was not otherwise
participating in the study, according to speed, accelera-
tion and no interferences, such as gait abnormalities or
extra body movements. The mean of these three
measurements was used for analysis. The ground reaction
forces were normalized for each dog’s BW and mean
peak vertical force (PVF) and mean vertical impulse were
used as variables. Only measurements from the more
severely affected limb at time W0 were used in the
analysis.
Table 2. Content of Zeel ad us. vet.
Zeel ad us. vet. Dil mg
Cartilago suis D6 5.0
Funiculus umbilicalis suis D6 5.0
Embryon totalis suis D6 5.0
Placenta totalis suis D6 5.0
Solanum dulcamara D3 25.0
Symphytum officinale e radice D6 25.0
Nadidum D8 5.0
Coenzyme A D8 5.0
Sanguinaria canadensis D4 7.5
Arnica montana D3 50.0
Sulfur D6 9.0
Natrium diethyloxalaceticum D8 5.0
Acidum alpha-liponicum D8 5.0
Toxicodendron quercifolium
e summitatibus rec
D2 25.0
The content of one 5.0ml ampoule of the low-dilution homeopathic
combination preparation (HCP): Zeel–injection solution. Mg of the
different dilutions in the ampoule (Dil=D2–D8 (often also marked as
2–8)=diluted 1:10 two to eight times). From the Heel company
veterinary guide, Baden-Baden, Germany 1997.
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Blood samples were collected from the dogs at each visit.
Kidney, liver and protein values [blood urea nitrogen
(BUN), creatinine, serum alanine aminotransferase
(ALAT), alkaline phosphatase (AFOS), total proteins
and albumin] were analyzed.
Statistical Analysis
The number of dogs needed in each group was calculated
with a two-tailed test. The sample size was sufficiently
large to detect a 47% difference in treatment outcome
(effective versus non-effective) with a statistical power of
0.8 and allowing for a 5% alpha error.
For the dogs that had used extra carprofen more than
three times per week at W8, we changed all their variables
values at evaluation W8 into the most negative value
measured at that time, separately for each variable.
This was done to counteract the effect of the taken
NSAID and enabled us to use the whole data in the first
statistical analyses.
For calculating the percentage of dogs per group that
improved between baseline and W8 and the odds ratio,
the results of each variable were converted into dichot-
omous responses of ‘improved’ and ‘not improved’.
Dogs that deteriorated and dogs with no change in the
evaluated variable were considered ‘not improved’.
The difference between the treatment groups and the
placebo where calculated using a Chi-Squared test. The
odds ratio was calculated using the common Mantel
Haenszel odds ratio estimate and the confidence interval
(CI) was set to 95%. An odds ratio over 1.0 indicated
a beneficial effect of the test treatments.
The change from baseline to W8 was also calculated
for each variable. The difference between the GLM and
placebo group was analyzed using the Mann–Whitney
test. The change from W0 to W8 in the force plate
variables was similar for the front and hind legs,
although the values were different. Therefore, force
plate data of all four legs were analyzed together. Dogs
that did not manage to get force plate results due to
major lameness were considered ‘not improved’ in the
dichotomous analyses and were excluded from the
median change data. A correlation test was used to
evaluate the association between the assessments of the
two veterinarians. Statistical significance was set at
P<0.05. Statistical tests were preformed using SPSS
12.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline
Seven of these 51 dogs were excluded from the material
at some time during the study because they did not meet
the medical inclusion criteria (operation on the affected
hip joint, a transverse vertebra (n=2), a cruciate
ligament injury, degenerative myelopathy, polyarthritis
of the phalanges and castration just prior to the third
visit). The baseline differences between groups were not
statistically significant (Table 1).
Dichotomous Responses
All major data are presented in Table 3. Four dogs (all in
the placebo group) used extra carprofen more than three
times per week at W8 and two dogs were not able to trot
over the force plate. When the data of all variables were
changed into dichotomous responses of either ‘improved’
or ‘not improved’, three of the variables [veterinary-
assessed mobility index (P=0.018), force plate PVF
(P=0.006) and pain VAS (P=0.043)] indicated sig-
nificantly more improved dogs in the HCP group
compared with the placebo group. The odds ratio for
the veterinary-assessed mobility index was 6.88 (95% CI
Table 3. Percentage of improved dogs and median (+range) of improvement from W0 to W8, for evaluated variables, per group
carprofen (n=15) HCP (n=14) Placebo (n=15)
Improved
P=
Improvement
Median (range), P=
Improved
P=
Improvement
Median (range), P=
Improved
(%)
Improvement
Median (range)
Veterinary mobility
index
66.7% 0.031 3 (0 to –8) 0.001 71.4% 0.018 1.5 (5 to 7) 0.015 26.7 3( 14 to 3)
Force plate PVF 66.7% 0.031 3.2 (8.2 to 1.8) 0.079 78.6% 0.006 2.3 (3.4 to 10.2) 0.028 26.7 0.9 (33.6 to 10)
Force plate Impulse 80.0% 0.011 0.4 (0.5 to 1.3) 0.009 64.3% 0.101 0.2 (1.3 to 1.3) 0.093 33.3 0.0 (3.3 to 0.8)
Chronic pain index 80.0% 0.028 9 (9 to 19) <0.001 57.1% 0.364 2 (6 to 9) 0.049 40.0 3( 25 to 8)
Pain VAS 85.7% 0.001 1.4 (6 to 8.4) <0.001 57.1% 0.043 0.2 (3.5 to 4.9) 0.020 20.0 1.7 (7 to 3.2)
Locomotion VAS 85.7% 0.002 3.1 (1.9 to 6.2) 0.001 57.1% 0.102 0.7 (5 to 4.8) 0.205 26.7 1( 6.6 to 5)
For each treatment group: First column: Percentage of dogs in the group that improved. Second column: Median (with range) of change from W0 to
W8 ((+)=improvement, ()=deterioration) in evaluated variables for the carprofen-, HCP- and placebo groups. P=Difference in improvement
between treatment groups and placebo (the force plate values here do not include two dogs for whom no results were obtained). (n, number of
patients per group; HCP, homeopathic combination product; Improved, percentage of dogs that improved per group; PVF, peak vertical force;
VAS, visual analogue scale).
468 Zeel for canine osteoarthritis1.35–35.06) indicating that a dog that had received the
HCP was 6.88 times more likely to have a positive
response than a dog that had received the placebo. The
odds ratio for the force plate PVF was 9.17 (95% CI
1.63–51.43), for the force plate impulse 3.24 (95% CI
0.69–15.20), for the owner-assessed chronic pain index
2.00 (95% CI 0.46–8.78), for the pain VAS 5.33 (95%
CI 1.02–27.76) and for the locomotion VAS 3.67 (95%
CI 0.77–17.43).
Medians (+ Range) of the Change from W0 to W8
The medians and ranges of the changes from W0 to W8 in
each variable are shown in Table 3. Two dogs from the
placebo group are excluded from the two force plate
evaluations. All variables showed a similar trend of
improvement, with carprofen being most efficient, pla-
cebo least, and HCP being between these two. In the
negative control group (placebo), all change medians
were on or below the ‘no change’ line, indicating
deterioration. There was a significant difference in four
of six variables in the extent of improvement between the
HCP and the placebo group; the veterinary-assessed
mobility index (P=0.015), the PVF (P=0.028), the
chronic pain index (P=0.049) and the pain VAS
(P=0.020). Data from W4 are not shown, as all values
were between the values of W0 and W8. Statistical
analyses were not performed on the results from W12,a s
so many dogs were using extra carprofen at this time.
Extra Carprofen
The use of the additional NSAIDs varied as follows: at
W4, 14% of the carprofen group, 28% of the HCP
group and 8% of the placebo group used extra NSAIDs
once a week or more often. At W8, the respective values
were 0, 14 and 27%, and at the follow up at W12, 33, 21
and 29%. Only the difference between the carprofen
group and the placebo group was significant (P=0.012)
at W8.
Complications and Side-Effects
All of the altered blood values and the clinical side-
effects were considered mild or within normal range.
No difference between groups was seen. One dog in the
placebo group was euthanized due to severe pain during
the follow-up period.
Discussion
We examined the effect of the HCP Zeel on OA in dogs.
Compared with the placebo group, the HCP treatment
gave significantly better results both as number of cases
that improved per group and as efficacy or extent of
improvement. Thus, the results of what apparently is the
first randomized, controlled, double-blinded study on the
use of a HCP on OA in dogs indicate that the treatment
indeed tends to have significant positive impact. The
results add to previous positive results on the use of this
HCP on OA in studies on humans (13,14), rabbits (16)
and horses (17), suggesting that the treatment may be
beneficial also for other species. To be noted is that,
compared with the placebo group, the group of dogs
being treated with carprofen improved even more. This is
in accordance with previous studies that have demon-
strated a treatment effect of 56–81% for carprofen and
only 23–38% for placebo (26,27). But, as carprofen and
other NSAIDs can potentially have severe side-effects
such as hepatic disease, renal toxicosis and irritation of
the gastrointestinal tract, ultimately leading to hemor-
rhagic ulcers and even death (28,29), it is of utmost
importance that we continue doing clinical research on all
alternative treatments for OA.
Other data also support our results: it is generally
accepted that seasonal differences influence OA, with
patients being worse in cold, damp and unstable weather
(in our study=W4–8) and better in dry (W0) and warm
(W12) weather (30,31). In the placebo group, a trend was
detectable; in the change of means between W0 and W8,
we could see deterioration in nearly all variables (negative
values in Table 3) and use of more extra NSAID; and
improving at follow up (W12) as the weather warmed up.
In the two treatment groups an opposite pattern was
detected. They demonstrated a positive effect during the
test period (W0–8) but worsened at the follow up (W12),
which can be speculated to indicate the positive effect
of the drugs and a worsening after discontinuation at
W8. The increase in the intake of extra NSAIDs at W12
in the carprofen group further supports this.
However, although significant differences between
groups were found in this study, it suffers from some
limitations that at the same time point to possibilities for
future research. Future studies should ideally ascertain
that the treatment group, as well as the positive and
negative control groups, is large enough to detect
difference even when data are lost. Having two dogs in
the placebo group that were not able to perform the runs
over the force plate and were therefore excluded from the
data, slightly ameliorated the median values for this
group, perhaps resulting in less significance in the treated
groups. Second, the location (hip or elbow), the multi-
tude (uni or bilateral) and severity of OA varied across
the dogs, leading to assessment problems e.g. using the
force plate due to transferring the weight to other legs.
Heterogeneity also leads to high variance; a problem in a
small study like ours, with a relatively moderate sample
size, and subsequently results in lower significance. Third,
the dose and mode of application of HCP in our study
was ½1 ampoule/day (depending on BW) in one oral
dose. However, the dosing and presentation of the Zeel
eCAM 2009;6(4) 469product has since changed; it is now given as a tablet and
at 300% of the dose used in this study. Furthermore, for
optimal results, Zeel is often combined with other
homeopathic products (such as Traumeel) in clinical
practice (1), but combining products was not suitable for
our protocol. Future research might want to assess effect
using different doses, methods of application or combi-
nations. Finally, as very little research on chronic pain
assessment for dogs still is available, it will make future
research easier when we have more validated scales to
use. Measuring ground reaction forces using a force plate
(32–35) were the most objective measurement used,
but they are not so reliable to use on a very variable
cohort. Validated owner-based scales are now also
becoming available and will maybe be used more in the
future (25,36–38).
Thus we must conclude that the results are intriguing,
as all positive results in homeopathic medicine. As the
study was rigorously carried out as a randomized,
double-controlled, double-blind trial and as the placebo
effect anyway should be smaller when evaluating dogs
and not humans, we can elaborate on a possible working
mechanism for this product. It seems plausible that the
treatment effects reported previously could have been
seen in this trial as well: in a randomized, sham-
controlled placebo study on rabbits with experimentally
induced knee OA, a significant difference in gross
morphology and in histopathological score was found
between the joints treated with HCP Zeel comp. and
those untreated (16). Also, cartilage slices incubated for
6 days in a medium containing Zeel showed better
preservation of structures than controls in an in vitro
study using methods of interference polarization micro-
scopy and x-ray difractometry for analysis (39).
An in vitro study (40) demonstrated that two of the
ingredients in our test product were able to inhibit
leucocyte elastase activity; Arnica montana D4 up to 70%
and Rhus toxicodendron (same as Toxicodendron querci-
folium in Table 2.) D3 up to 77% (elastase is an enzyme
that is released during inflammatory reactions and
attacks the articular cartilage which is rich in proteogly-
cans). In a second study (41), Rhus toxicodendron at D1
and D2 potencies, as well as 10 other plant extracts, was
shown to inhibit cell growth of human cutaneous F54
fibroblasts.
Recently, a reconstituted Zeel comp. N combination
(as well as its constituent mother tinctures) were reported
to show distinct inhibitory effects on the production of
Leukotriene B4 by 5-lipoxygenase (5-LOX) and on the
synthesis of prostaglandin PGE2 by COX-1 and 2
enzymes. Together with the other inhibiting activities,
this dual inhibition of both LOX- and COX-metabolic
pathways may offer an explanation for the reported
clinical efficacy and favorable gastrointestinal tolerability
of the original Zeel comp. N remedy (42) and of the
veterinarian product we used in this study, that was very
similar.
In conclusion, the results of this relatively small study
of dogs with moderate to severe OA showed that dogs
receiving the HCP Zeel for 8 weeks had significantly
less pain than their placebo peers. Homeopathy as a
treatment is often seen as controversial, so this positive
treatment result for dogs for this low-dilution HCP
should be of major interest for human OA researchers
and clinicians, alike. As chronic pain due to OA is
a major reason for decreased quality of life nowadays,
both for humans and dogs, we should proceed with more
studies in this direction.
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